Umbralisib, a Novel PI3Kδ and Casein Kinase-1ε Inhibitor, in Relapsed or Refractory Chronic Lymphocytic Leukaemia and Lymphoma: an Open-label, Phase 1, Dose-escalation, First-in-human Study

Drug Category : Array
Conference Category : Array
Lead Author : Burris H, et al.
Published Date : 20/02/2018
Download Link : https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30082-2/fulltext
Download Text :
Popup Confirmation? :
site-sidebar-layout : default
ast-site-content-layout : default
site-content-style : default
site-sidebar-style : default
theme-transparent-header-meta : default
stick-header-meta : default
astra-migrate-meta-layouts : set
Scroll to Top